As reported in the journal Arthritis & Rheumatology, the drug febuxostat reduced gout flares in a double-blind, placebo-controlled study of 314 adults with early gout.
As reported in the journal Arthritis & Rheumatology, the drug febuxostat reduced gout flares in a double-blind, placebo-controlled study of 314 adults with early gout. Febuxostat treatment also reduced synovitis—or inflammation of the joint lining detected by MRI scanning —over a 2-year period compared with placebo.
Febuxostat treats high urate in the blood of patients with gout.
“Current clinical practice guidelines do not recommend routine use of urate-lowering therapy for people after the first gout flare. This study indicates that even for people who have had only 1 or 2 prior gout flares, urate-lowering therapy to reduce serum urate below 6mg/dL may have benefit in reducing future flares,” said Dr. Nicola Dalbeth, lead author of the study.
Additional Information
Link to Study: http://onlinelibrary.wiley.com/doi/10.1002/art.40233/full
About Journal
Arthritis & Rheumatology, an official journal of the American College of Rheumatology, is a peer-reviewed publication for scientists and clinicians interested in the natural history, pathophysiology, treatment, and outcome of the rheumatic diseases. Arthritis & Rheumatology publishes the highest quality basic and clinical research related to the rheumatic diseases, encompassing a wide range of areas of investigative activity. In addition, the journal publishes review articles, editorials, and other educational material intended for both researchers and clinicians. Serving the worldwide community of rheumatology investigators and clinicians, Arthritis & Rheumatology is known internationally as a top rheumatology research journal.
Penny Smith
Tel: +44 (0)1243 770448
sciencenewsroom@wiley.com